应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
01801 信达生物
未开盘 03-25 16:08:03
39.150
-1.200
-2.97%
最高
40.700
最低
38.850
成交量
795.37万
今开
40.050
昨收
40.350
日振幅
4.58%
总市值
641.28亿
流通市值
641.28亿
总股本
16.38亿
成交额
3.14亿
换手率
0.49%
流通股本
16.38亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
信达生物03月11日主力净流入624万元 散户资金抛售
市场透视 · 03-11
信达生物03月11日主力净流入624万元 散户资金抛售
信达生物03月07日遭主力抛售2389万元
市场透视 · 03-07
信达生物03月07日遭主力抛售2389万元
信达生物盘中异动 股价大涨5.11%
市场透视 · 03-06
信达生物盘中异动 股价大涨5.11%
中证港股通医药卫生综合指数上涨2.5%，前十大权重包含信达生物等
金融界 · 03-05
中证港股通医药卫生综合指数上涨2.5%，前十大权重包含信达生物等
【券商聚焦】海通国际维持信达生物(01801)“优大于市”评级 指其未来创新研发有望持续兑现
金吾财讯 · 03-04
【券商聚焦】海通国际维持信达生物(01801)“优大于市”评级 指其未来创新研发有望持续兑现
国泰君安：国产创新药全球竞争力凸显 经营拐点临近
智通财经 · 03-03
国泰君安：国产创新药全球竞争力凸显 经营拐点临近
头对头帕博利珠单抗，信达生物IBI363（PD-1/IL-2α-bias双特异性抗体融合蛋白）首个关键注册临床研究完成首例受试者给药，用于治疗黑色素瘤
美通社 · 03-03
头对头帕博利珠单抗，信达生物IBI363（PD-1/IL-2α-bias双特异性抗体融合蛋白）首个关键注册临床研究完成首例受试者给药，用于治疗黑色素瘤
天风证券：中国创新药产业趋势已较为明确并迅速加强 有望共享全球药品销售市场
智通财经 · 03-02
天风证券：中国创新药产业趋势已较为明确并迅速加强 有望共享全球药品销售市场
高盛：维持小米集团-W(01810)“买入”评级 目标价58港元
智通财经 · 02-28
高盛：维持小米集团-W(01810)“买入”评级 目标价58港元
信达生物盘中异动 早盘急速下挫5.09%报41.000港元
市场透视 · 02-28
信达生物盘中异动 早盘急速下挫5.09%报41.000港元
港股概念追踪|百济神州成为国内“创新药一哥” 机构看好创新药2025年估值修复（附概念股）
智通财经 · 02-26
港股概念追踪|百济神州成为国内“创新药一哥” 机构看好创新药2025年估值修复（附概念股）
【港股异动 | 信达生物(01801.HK)午后涨超7% 】信达生物(01801.HK)午后涨超7%，截至发稿，涨5.82%，报42.7港元，成交额4.37亿港元。
金融界 · 02-26
【港股异动 | 信达生物(01801.HK)午后涨超7% 】信达生物(01801.HK)午后涨超7%，截至发稿，涨5.82%，报42.7港元，成交额4.37亿港元。
港股异动 | 信达生物(01801)午后涨超7% 信迪利单抗癌症联合疗法申报上市 新药IBI3002获批临床
智通财经 · 02-26
港股异动 | 信达生物(01801)午后涨超7% 信迪利单抗癌症联合疗法申报上市 新药IBI3002获批临床
信达生物盘中异动 快速拉升5.08%
市场透视 · 02-26
信达生物盘中异动 快速拉升5.08%
招银国际：内地药品价格政策有望优化 医疗AI加速商业化落地
智通财经 · 02-25
招银国际：内地药品价格政策有望优化 医疗AI加速商业化落地
【券商聚焦】中信建投：政策与技术齐驱 我国创新药行业竞争力不断攀升
金吾财讯 · 02-24
【券商聚焦】中信建投：政策与技术齐驱 我国创新药行业竞争力不断攀升
信达生物宣布首个中国研发的CTLA-4单抗伊匹木单抗注射液联合信迪利单抗用于结肠癌新辅助治疗的新药上市申请获受理并纳入优先审评
美通社 · 02-24
信达生物宣布首个中国研发的CTLA-4单抗伊匹木单抗注射液联合信迪利单抗用于结肠癌新辅助治疗的新药上市申请获受理并纳入优先审评
【信达生物(01801.HK)：伊匹木单抗注射液联合信迪利单抗用于结肠癌新辅助治疗的新药上市申请获国家药品监督管理局受理并纳入优先审评】信达生物(01801.HK)公布，伊匹木单抗注射液(抗细胞毒T淋巴细胞相关抗原4(CTLA-4单抗，研发代号：IBI310)联合信迪利单抗用于可切除的微卫星高度不稳定型(MSI-H)或错配修复缺陷型(dMMR)结肠癌患者的新辅助治疗的新药上市申请(NDA)已获中国国家药品监督管理局(NMPA)药品审评中心(CDE)受理并纳入优先审评程序。伊匹木单抗是首个递交NDA的中国研发的CTLA-4单抗，同时，这也是信迪利单抗奠定其肿瘤免疫治疗领先品牌的又一里程碑。
金融界 · 02-24
【信达生物(01801.HK)：伊匹木单抗注射液联合信迪利单抗用于结肠癌新辅助治疗的新药上市申请获国家药品监督管理局受理并纳入优先审评】信达生物(01801.HK)公布，伊匹木单抗注射液(抗细胞毒T淋巴细胞相关抗原4(CTLA-4单抗，研发代号：IBI310)联合信迪利单抗用于可切除的微卫星高度不稳定型(MSI-H)或错配修复缺陷型(dMMR)结肠癌患者的新辅助治疗的新药上市申请(NDA)已获中国国家药品监督管理局(NMPA)药品审评中心(CDE)受理并纳入优先审评程序。伊匹木单抗是首个递交NDA的中国研发的CTLA-4单抗，同时，这也是信迪利单抗奠定其肿瘤免疫治疗领先品牌的又一里程碑。
信达生物(01801)：伊匹木单抗注射液联合信迪利单抗用于结肠癌新辅助治疗的新药上市申请获国家药品监督管理局受理并纳入优先审评
智通财经 · 02-24
信达生物(01801)：伊匹木单抗注射液联合信迪利单抗用于结肠癌新辅助治疗的新药上市申请获国家药品监督管理局受理并纳入优先审评
信达生物信迪利单抗癌症联合疗法申报上市，科济药业CAR-T细胞疗法拟纳入突破性治疗品种
医药经济报 · 02-22
信达生物信迪利单抗癌症联合疗法申报上市，科济药业CAR-T细胞疗法拟纳入突破性治疗品种
加载更多
公司概况
公司名称：
信达生物
所属市场：
SEHK
上市日期：
--
主营业务：
信达生物制药是一家主要从事生物制药的投资控股公司。该公司及其子公司从事抗体及蛋白质医药产品的研发、药品的销售及分销，以及提供咨询及研发服务。该公司的主要产品为达伯舒（信迪利单抗注射液），用于治疗复发或难治性经典霍奇金淋巴瘤。该公司的产品还包括阿达木单抗生物类似药IBI-303，用于治疗类风湿性关节炎、强直性脊柱炎及银屑病。贝伐珠单抗生物类似药IBI-305，用于治疗转移性结直肠癌及晚期、转移性或复发性非小细胞肺癌（NSCLC）。利妥昔单抗生物类似药IBI-301，用于治疗非霍奇金淋巴瘤及慢性淋巴细胞白血病。该公司的产品应用于肿瘤、代谢、免疫学及眼底病等领域。
发行价格：
--
{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"信达生物","latestPrice":39.15,"timestamp":1742890083014,"preClose":40.35,"halted":0,"volume":7953742,"delay":0,"floatShares":1638000000,"shares":1638000000,"eps":-0.7052815014694678,"marketStatus":"未开盘","change":-1.2,"latestTime":"03-25 16:08:03","open":40.05,"high":40.7,"low":38.85,"amount":313838717,"amplitude":0.045849,"askPrice":39.15,"askSize":29500,"bidPrice":39.1,"bidSize":9500,"shortable":3,"etf":0,"ttmEps":-0.8552024171111353,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1742952600000},"marketStatusCode":0,"adr":0,"listingDate":1540915200000,"exchange":"SEHK","adjPreClose":40.35,"openAndCloseTimeList":[[1742866200000,1742875200000],[1742878800000,1742889600000]],"volumeRatio":0.4980003516495122,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK","impliedVol":0.5524,"impliedVolPercentile":0.5551},"requestUrl":"/m/hq/s/01801","defaultTab":"news","newsList":[{"id":"2518713219","title":"信达生物03月11日主力净流入624万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2518713219","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518713219?lang=zh_cn&edition=full","pubTime":"2025-03-11 16:15","pubTimestamp":1741680919,"startTime":"0","endTime":"0","summary":"03月11日, 信达生物股价涨2.05%，报收39.80元，成交金额4.56亿元，换手率0.70%，振幅5.51%，量比0.85。信达生物今日主力资金净流入624万元，上一交易日主力净流出2714万元。该股近5个交易日下跌1.98%，主力资金累计净流出6635万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入1.13亿元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311165331a1d49b68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311165331a1d49b68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2328871848.SGD","BK1161","LU2488822045.USD","01801","LU1969619763.USD","BK1583","BK1589"],"gpt_icon":0},{"id":"2517053311","title":"信达生物03月07日遭主力抛售2389万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517053311","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517053311?lang=zh_cn&edition=full","pubTime":"2025-03-07 16:15","pubTimestamp":1741335350,"startTime":"0","endTime":"0","summary":"03月07日, 信达生物股价跌0.37%，报收40.20元，成交金额4.73亿元，换手率0.72%，振幅4.21%，量比0.77。信达生物今日主力资金净流出2389万元，连续3日净流出，上一交易日主力净流出159万元。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为53.85%，平均跌幅为2.67%。该股近5个交易日下跌0.37%，主力资金累计净流出1779万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入1.30亿元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307170155a263dc93&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307170155a263dc93&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","LU2328871848.SGD","BK1589","LU1969619763.USD","01801","BK1161","BK1583"],"gpt_icon":0},{"id":"2517708789","title":"信达生物盘中异动 股价大涨5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517708789","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517708789?lang=zh_cn&edition=full","pubTime":"2025-03-06 09:47","pubTimestamp":1741225663,"startTime":"0","endTime":"0","summary":"2025年03月06日早盘09时47分，信达生物股票出现波动，股价大幅上涨5.11%。截至发稿，该股报42.200港元/股，成交量416.367万股，换手率0.25%，振幅3.74%。信达生物股票所在的药品行业中，整体涨幅为0.30%。其相关个股中，德琪医药-B、兆科眼科-B、信达生物涨幅较大，振幅较大的相关个股有顺腾国际控股、德琪医药-B、兆科眼科-B，振幅分别为11.54%、8.16%、6.22%。信达生物公司简介：信达生物制药是一家从事药物研发、生产及销售的投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306094743abea7509&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306094743abea7509&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","BK1583","BK1589","BK1161","LU1969619763.USD","01801","LU2328871848.SGD"],"gpt_icon":0},{"id":"2517153709","title":"中证港股通医药卫生综合指数上涨2.5%，前十大权重包含信达生物等","url":"https://stock-news.laohu8.com/highlight/detail?id=2517153709","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517153709?lang=zh_cn&edition=full","pubTime":"2025-03-05 20:09","pubTimestamp":1741176540,"startTime":"0","endTime":"0","summary":"数据统计显示，中证港股通医药卫生综合指数近一个月上涨14.07%，近三个月上涨10.66%，年至今上涨15.80%。据了解，中证港股通医药卫生综合指数从港股通范围内选取50只流动性较好、市值较大的医疗卫生行业上市公司证券作为指数样本，以反映港股通范围内医药卫生上市公司证券的整体表现。从中证港股通医药卫生综合指数持仓样本的行业来看，医药卫生占比100.00%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/05200948546293.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["HSCEI","LU2488822045.USD","LU1969619763.USD","BK1583","BK1589","YANG","BK1161","LU2328871848.SGD","HSTECH","000008.SH","01801"],"gpt_icon":1},{"id":"2516619976","title":"【券商聚焦】海通国际维持信达生物(01801)“优大于市”评级 指其未来创新研发有望持续兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2516619976","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516619976?lang=zh_cn&edition=full","pubTime":"2025-03-04 12:39","pubTimestamp":1741063159,"startTime":"0","endTime":"0","summary":"金吾财讯 | 海通国际发研报指，信达生物 2023年实现营收62.1亿元，其中产品收入57.3亿元，同比增长38.4%。产品收入快速增长主要得益于PD-1的优先卡位及迅速放量；其他商业化产品亦保持良好增长。公司预计2025年实现EBITDA盈亏平衡，2027年实现国内产品营收200亿元。该行看好公司全球创新研发能力、优质管线的价值和衔接能力、未来创新研发有望持续兑现。1)PD-1营收稳健增长有望持续、该行预测生物类似药集采风险对营收影响可控。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1954301","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"gpt_icon":0},{"id":"2516577974","title":"国泰君安：国产创新药全球竞争力凸显 经营拐点临近","url":"https://stock-news.laohu8.com/highlight/detail?id=2516577974","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516577974?lang=zh_cn&edition=full","pubTime":"2025-03-03 14:00","pubTimestamp":1740981619,"startTime":"0","endTime":"0","summary":"国泰君安主要观点如下：全球竞争力凸显，经营扭亏拐点临近国产创新药逐渐展现出全球竞争力：据医药魔方统计，2024年在中国首发获批的新药达39款，占全球近40%，全球在研first in class新药中的国产品种占比已达24%，中国企业全年license-out交易的首付款和总金额分别达41亿和519亿美元。安徽省医保局发文将牵头2025年全国生物药品联盟集采，或将包括生物类似药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1256802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","BK1147","IE00B5MMRT66.SGD","BK1161","LU0417516571.SGD","09926","LU1969619763.USD","601211","BK1574","BK1500","BK1564","LU1794554557.SGD","IE00B543WZ88.USD","BK0184","00013","01801","06160","06990","LU0348783233.USD","BK1191","BK1587","BK0183","LU0307460666.USD","LU1720050803.USD","BK0012","06978","LU2488822045.USD","BK0028","LU0588546209.SGD","BK0276","BK0188","LU2328871848.SGD","LU0196878994.USD","IE00BPRC5H50.USD","BK1589","LU0348784397.USD","09969","02611","BK1583","159992","BK0201"],"gpt_icon":0},{"id":"2516452525","title":"头对头帕博利珠单抗，信达生物IBI363（PD-1/IL-2α-bias双特异性抗体融合蛋白）首个关键注册临床研究完成首例受试者给药，用于治疗黑色素瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2516452525","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516452525?lang=zh_cn&edition=full","pubTime":"2025-03-03 08:00","pubTimestamp":1740960000,"startTime":"0","endTime":"0","summary":"目前，IBI363已开出首个关键注册临床研究，用于治疗未经免疫治疗的粘膜型和肢端型黑色素瘤。另外，IBI363已获美国FDA两项快速通道资格认定，分别用于治疗鳞状非小细胞肺癌和黑色素瘤。截至目前，信达生物患者援助项目已惠及20余万普通患者，药物捐赠总","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4631081_ZH31081_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["01801","LU2328871848.SGD","BK4139","IVBIY","LU2488822045.USD","BK1161","LU1169589451.USD","PD","BK4023","LU1969619763.USD","BK1583","LU1169590202.USD","BK1589"],"gpt_icon":0},{"id":"2516513487","title":"天风证券：中国创新药产业趋势已较为明确并迅速加强 有望共享全球药品销售市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2516513487","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516513487?lang=zh_cn&edition=full","pubTime":"2025-03-02 17:25","pubTimestamp":1740907559,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，天风证券发布研究报告称，站在当前时点，中国创新药行业的产业趋势已较为明确并迅速加强。一个是创新品种在中国获批上市，带来收入以及利润;一个是创新能力加强，BIC 潜力管线海外权益授出带来收入以及利润。从节奏来看，天风证券认为两个逻辑都处在加强阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1256601.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02105","BK0276","01801","BK1583","02256","LU2328871848.SGD","06978","BK1574","LU2488822045.USD","BK1191","01952","601162","BK1589","BK1161","159992","LU1969619763.USD","03692"],"gpt_icon":0},{"id":"2514603314","title":"高盛：维持小米集团-W(01810)“买入”评级 目标价58港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514603314","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514603314?lang=zh_cn&edition=full","pubTime":"2025-02-28 16:17","pubTimestamp":1740730637,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛发布研报称，维持小米集团-W(01810)“买入”评级，目标价58港元。高盛指，集团昨日(27日)举行春季新产品发表活动，显示小米高端化策略以及持续发展“人x车x家”生态系统，进一步超越消费者期望。更重要的是，该行预料旗下电动车、智能手机和AIoT领域等新产品将具有高于行业的性价比，将支撑小米品牌进入高端市场，有助集团不断扩大具有价值的用户群或生态系统，并增强其收入或利润成长的可持续性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1256096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01810","01801"],"gpt_icon":0},{"id":"2514336437","title":"信达生物盘中异动 早盘急速下挫5.09%报41.000港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514336437","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514336437?lang=zh_cn&edition=full","pubTime":"2025-02-28 10:05","pubTimestamp":1740708322,"startTime":"0","endTime":"0","summary":"2025年02月28日早盘10时05分，信达生物股票出现波动，股价大幅下挫5.09%。截至发稿，该股报41.000港元/股，成交量349万股，换手率0.21%，振幅6.37%。资金方面，该股资金流入5713.63万港元，流出5685.08万港元。机构评级方面，在所有22家参与评级的机构中，91%的券商给予买入建议，9%的券商给予持有建议，无券商给予卖出建议。信达生物股票所在的药品行业中，整体跌幅为0.42%。信达生物公司简介：信达生物制药是一家从事药物研发、生产及销售的投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228100522a2572008&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228100522a2572008&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801","LU1969619763.USD","BK1583","BK1161","BK1589","LU2328871848.SGD","LU2488822045.USD"],"gpt_icon":0},{"id":"2514900875","title":"港股概念追踪|百济神州成为国内“创新药一哥” 机构看好创新药2025年估值修复（附概念股）","url":"https://stock-news.laohu8.com/highlight/detail?id=2514900875","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514900875?lang=zh_cn&edition=full","pubTime":"2025-02-26 13:53","pubTimestamp":1740549201,"startTime":"0","endTime":"0","summary":"2月21日，百济神州以27亿元市值差距超越恒瑞医药，成为“创新药一哥”。百济神州的创新药收入增长迅猛，其BTK抑制剂泽布替尼全球销售额突出。百济神州市值新高有业绩支撑，预计2025年全年经营利润为正。国金证券发布研究报告称，建议继续贯彻AI医药+创新药2025年医药投资两大布局主线。该行表示，看好行业估值修复。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1254498.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","IE00B5MMRT66.SGD","BK1161","LU0417516571.SGD","09926","LU1969619763.USD","BK1574","BK1500","LU1794554557.SGD","IE00B543WZ88.USD","01801","06160","HSCEI","LU0348783233.USD","BK4139","LU0307460666.USD","LU1720050803.USD","06978","LU2488822045.USD","YANG","HSTECH","ONC","LU0588546209.SGD","LU2328871848.SGD","IE00BPRC5H50.USD","BK1589","LU0348784397.USD","BK0239","BK1583","159992","688235"],"gpt_icon":1},{"id":"2514707020","title":"【港股异动 | 信达生物(01801.HK)午后涨超7% 】信达生物(01801.HK)午后涨超7%，截至发稿，涨5.82%，报42.7港元，成交额4.37亿港元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514707020","media":"金融界","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514707020?lang=zh_cn&edition=full","pubTime":"2025-02-26 13:41","pubTimestamp":1740548478,"startTime":"0","endTime":"0","summary":"信达生物(01801.HK)午后涨超7%，截至发稿，涨5.82%，报42.7港元，成交额4.37亿港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/26134148395947.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1583","BK1589","LU1969619763.USD","LU2488822045.USD","BK1161","LU2328871848.SGD","01801"],"gpt_icon":0},{"id":"2514909070","title":"港股异动 | 信达生物(01801)午后涨超7% 信迪利单抗癌症联合疗法申报上市 新药IBI3002获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2514909070","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514909070?lang=zh_cn&edition=full","pubTime":"2025-02-26 13:39","pubTimestamp":1740548351,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，信达生物午后涨超7%，截至发稿，涨5.82%，报42.7港元，成交额4.37亿港元。此外，2月24日，中国国家药监局药品审评中心官网最新公示，信达生物申报的1类新药IBI3002获批临床，拟开发治疗哮喘。根据信达生物公开资料，IBI3002是其自主研发的一款抗IL-4Rα/TSLP双特异性抗体，目前正在澳大利亚开展1期临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1254483.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | 信达生物(01801)午后涨超7% 信迪利单抗癌症联合疗法申报上市 新药IBI3002获批临床","news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01801","LU1969619763.USD","BK1589","LU2488822045.USD","LU2328871848.SGD","BK1583"],"gpt_icon":0},{"id":"2514709930","title":"信达生物盘中异动 快速拉升5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514709930","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514709930?lang=zh_cn&edition=full","pubTime":"2025-02-26 13:29","pubTimestamp":1740547785,"startTime":"0","endTime":"0","summary":"2025年02月26日下午盘13时29分，信达生物股票出现异动，股价快速拉升5.08%。信达生物股票所在的药品行业中，整体涨幅为0.30%。消息层面，截至13时29分，《信达生物PD-1联合疗法申报上市获受理；艾美疫苗全面接入DeepSeek大模型》资讯为影响信达生物的重要信息。该信息摘要如下：NO.1信达生物PD-1联合疗法申报上市获受理。其中，信迪利单抗是一种PD-1抑制剂，已在国内获批8项适应证。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022613294598931767&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022613294598931767&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","LU2488822045.USD","BK1161","BK1583","01801","LU2328871848.SGD","LU1969619763.USD"],"gpt_icon":0},{"id":"2514129084","title":"招银国际：内地药品价格政策有望优化 医疗AI加速商业化落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2514129084","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514129084?lang=zh_cn&edition=full","pubTime":"2025-02-25 09:50","pubTimestamp":1740448233,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，维持内地医药行业“优于大市评级”。MSCI中国医疗指数2025年初至今累计上涨11.5%，跑输MSCI中国指数1.2%。受益于国内药品价格政策优化、国内宏观环境改善以及海外降息预期，医药行业有望在2025年继续迎来估值修复。报告指，丙类医保目录年内即将落地，创新药将覆盖获得更好的支付环境；医疗设备招标加速复苏，将推动国产医疗设备企业盈利复苏。该行看好行业估值修复，推荐买入信达生物(01801)、百济神州(06160)、三生制药(01530)、联影医疗(688271.SH)、巨子生物(02367)、药明康德(02359)、科伦博泰生物-B(06990)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1253807.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0588546209.SGD","BK1500","BK1593","LU1969619763.USD","BK1207","LU0708995583.HKD","01530","BK1141","LU1046422090.SGD","LU2488822045.USD","02367","LU2045819591.USD","BK1588","LU0320764599.SGD","LU0052750758.USD","LU2125910500.SGD","02359","BK1589","LU2242644610.SGD","LU0307460666.USD","BK1576","BK1583","BK1161","06160","LU2328871848.SGD","150261","01801"],"gpt_icon":0},{"id":"2513767989","title":"【券商聚焦】中信建投：政策与技术齐驱 我国创新药行业竞争力不断攀升","url":"https://stock-news.laohu8.com/highlight/detail?id=2513767989","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513767989?lang=zh_cn&edition=full","pubTime":"2025-02-24 09:18","pubTimestamp":1740359916,"startTime":"0","endTime":"0","summary":"该行表示，我国创新药行业在全球的竞争力正不断攀升。国家政策大力鼓励创新药发展，新技术的涌现也推动着行业快速前行，出海迎来了全新契机，基于此，该行对创新药行业的前景保持持续乐观的态度。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1953707","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0326950275.SGD","LU0501845795.SGD","LU2488822045.USD","01801","LU0348783233.USD","BK1589","LU1226287792.SGD","LU2328871848.SGD","LU1226287875.USD","LU0067412154.USD","601066","06160","BK1161","LU0880133367.SGD","IE00BZ08YT58.USD","IE0008369823.USD","LU1226288253.USD","01177","LU1720050803.USD","LU1951186391.HKD","LU1152091754.HKD","06978","LU0588546209.SGD","LU1226287529.USD","LU1960683339.HKD","IE00B543WZ88.USD","LU1152091168.USD","LU1807302812.USD","BK1574","BK1587","BK1583","00013","01093","03692","159992","IE00B5MMRT66.SGD","SG9999004220.SGD","BK1500","09926","BK1521","LU1969619763.USD","BK1191","IE00BZ08YR35.GBP","LU1008478684.HKD","LU1226288170.HKD","LU1993786604.SGD","LU0072913022.USD","IE0008368742.USD","IE00B031HY20.USD","LU0307460666.USD"],"gpt_icon":0},{"id":"2513976262","title":"信达生物宣布首个中国研发的CTLA-4单抗伊匹木单抗注射液联合信迪利单抗用于结肠癌新辅助治疗的新药上市申请获受理并纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2513976262","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513976262?lang=zh_cn&edition=full","pubTime":"2025-02-24 07:52","pubTimestamp":1740354720,"startTime":"0","endTime":"0","summary":"伊匹木单抗是首个递交NDA的中国研发的CTLA-4单抗，同时，这也是信迪利单抗奠定其肿瘤免疫治疗领先品牌的又一里程碑。研究旨在评估伊匹木单抗联合信迪利单抗新辅助治疗可切除的MSI-H/dMMR结肠癌对比直接根治性手术的有效性和安全性。伊匹木单抗联合信迪利单抗组与信迪利单抗单药组术后病理淋巴结阳性率分别为3.9%与15.9%。伊匹木单抗联合信迪利单抗用于可切除的MSI-H/dMMR结肠癌患者的新辅助治疗的NDA在NMPA优先审评中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4625139_ZH25139_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["01801","PP","BK4017","LU2328871848.SGD","IVBIY","BK1161","LU1969619763.USD","BK1589","BK4139","ALK","BK4585","BK4500","BK4588","CDE","BK4008","BK1583","LU2488822045.USD"],"gpt_icon":0},{"id":"2513695217","title":"【信达生物(01801.HK)：伊匹木单抗注射液联合信迪利单抗用于结肠癌新辅助治疗的新药上市申请获国家药品监督管理局受理并纳入优先审评】信达生物(01801.HK)公布，伊匹木单抗注射液(抗细胞毒T淋巴细胞相关抗原4(CTLA-4单抗，研发代号：IBI310)联合信迪利单抗用于可切除的微卫星高度不稳定型(MSI-H)或错配修复缺陷型(dMMR)结肠癌患者的新辅助治疗的新药上市申请(NDA)已获中国国家药品监督管理局(NMPA)药品审评中心(CDE)受理并纳入优先审评程序。伊匹木单抗是首个递交NDA的中国研发的CTLA-4单抗，同时，这也是信迪利单抗奠定其肿瘤免疫治疗领先品牌的又一里程碑。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513695217","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513695217?lang=zh_cn&edition=full","pubTime":"2025-02-24 07:37","pubTimestamp":1740353863,"startTime":"0","endTime":"0","summary":"信达生物(01801.HK)公布，伊匹木单抗注射液(抗细胞毒T淋巴细胞相关抗原4(CTLA-4单抗，研发代号：IBI310)联合信迪利单抗用于可切除的微卫星高度不稳定型(MSI-H)或错配修复缺陷型(dMMR)结肠癌患者的新辅助治疗的新药上市申请(NDA)已获中国国家药品监督管理局(NMPA)药品审评中心(CDE)受理并纳入优先审评程序。伊匹木单抗是首个递交NDA的中国研发的CTLA-4单抗，同时，这也是信迪利单抗奠定其肿瘤免疫治疗领先品牌的又一里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/24073748332964.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2506951875.HKD","LU2272731600.USD","BK1161","MSI","LU2065169927.USD","IE0034235188.USD","LU1969619763.USD","LU2125909759.SGD","LU2322448791.USD","LU2023250504.SGD","CDE","LU1992135399.USD","LU2023250843.SGD","BK1583","LU0950375773.USD","01801","LU2328871848.SGD","LU1923622291.USD","BK1589","LU2065171311.SGD","LU2247934214.USD","LU2506952097.USD","LU0823417653.USD","LU2506952170.USD","LU0823417737.USD","LU2473716301.USD","LU1992135472.HKD","LU2506951958.HKD","LU1917777945.USD","LU2272731865.HKD","LU2065170008.USD","LU0354030438.USD","BK4020","LU1974910355.USD","LU2488822045.USD","IE00B775SV38.USD","LU2065171402.SGD","IE00B3S45H60.SGD","LU2106854487.HKD","BK4017","BK4588","LU0354030511.USD","LU2125909916.SGD","LU2322448957.HKD","LU2272731782.SGD","BK4585"],"gpt_icon":0},{"id":"2513766014","title":"信达生物(01801)：伊匹木单抗注射液联合信迪利单抗用于结肠癌新辅助治疗的新药上市申请获国家药品监督管理局受理并纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2513766014","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513766014?lang=zh_cn&edition=full","pubTime":"2025-02-24 07:33","pubTimestamp":1740353607,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物 公布，伊匹木单抗注射液(抗细胞毒T淋巴细胞相关抗原4(CTLA-4单抗，研发代号：IBI310)联合信迪利单抗用于可切除的微卫星高度不稳定型(MSI-H)或错配修复缺陷型(dMMR)结肠癌患者的新辅助治疗的新药上市申请(NDA)已获中国国家药品监督管理局(NMPA)药品审评中心(CDE)受理并纳入优先审评程序。研究旨在评估伊匹木单抗联合信迪利单抗新辅助治疗可切除的MSI-H/dMMR结肠癌对比直接根治性手术的有效性和安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1253170.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"信达生物(01801)：伊匹木单抗注射液联合信迪利单抗用于结肠癌新辅助治疗的新药上市申请获国家药品监督管理局受理并纳入优先审评","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1969619763.USD","LU2328871848.SGD","01801","BK1583","LU2488822045.USD","BK1589","BK1161"],"gpt_icon":0},{"id":"2513279971","title":"信达生物信迪利单抗癌症联合疗法申报上市，科济药业CAR-T细胞疗法拟纳入突破性治疗品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2513279971","media":"医药经济报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513279971?lang=zh_cn&edition=full","pubTime":"2025-02-22 20:05","pubTimestamp":1740225953,"startTime":"0","endTime":"0","summary":"信达生物信迪利单抗癌症联合疗法申报上市今日，中国国家药监局药品审评中心官网最新公示，信达生物申报的伊匹木单抗注射液和信迪利单抗注射液的上市申请获得受理。公开资料显示，这是信达生物在研的抗CTLA-4单抗IBI310与抗PD-1单抗信迪利单抗联合疗法。公开资料显示，这是科济药业在研的靶向Claudin18.2蛋白的自体CAR-T细胞候选产品舒瑞基奥仑赛注射液，该产品已经在针对G/GEJ腺癌的中国关键2期临床试验中取得阳性结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222201032abd89de3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222201032abd89de3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","LU2328871848.SGD","01801","BK1574","BK1161","LU2488822045.USD","BK1589","02171","LU1969619763.USD","BK1583","BK1585"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":-0.0404},{"period":"1month","weight":-0.0612},{"period":"3month","weight":0.0936},{"period":"6month","weight":-0.1261},{"period":"1year","weight":0.0496},{"period":"ytd","weight":0.0697}],"compareEarnings":[{"period":"1week","weight":-0.0564},{"period":"1month","weight":-0.0057},{"period":"3month","weight":0.1615},{"period":"6month","weight":0.1716},{"period":"1year","weight":0.4171},{"period":"ytd","weight":0.1637}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"信达生物制药是一家主要从事生物制药的投资控股公司。该公司及其子公司从事抗体及蛋白质医药产品的研发、药品的销售及分销，以及提供咨询及研发服务。该公司的主要产品为达伯舒（信迪利单抗注射液），用于治疗复发或难治性经典霍奇金淋巴瘤。该公司的产品还包括阿达木单抗生物类似药IBI-303，用于治疗类风湿性关节炎、强直性脊柱炎及银屑病。贝伐珠单抗生物类似药IBI-305，用于治疗转移性结直肠癌及晚期、转移性或复发性非小细胞肺癌（NSCLC）。利妥昔单抗生物类似药IBI-301，用于治疗非霍奇金淋巴瘤及慢性淋巴细胞白血病。该公司的产品应用于肿瘤、代谢、免疫学及眼底病等领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.056031},{"month":2,"riseRate":0.714286,"avgChangeRate":0.11927},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.048078},{"month":4,"riseRate":0.666667,"avgChangeRate":0.022046},{"month":5,"riseRate":0.333333,"avgChangeRate":0.006538},{"month":6,"riseRate":0.666667,"avgChangeRate":0.118103},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.029935},{"month":8,"riseRate":0.833333,"avgChangeRate":0.002206},{"month":9,"riseRate":0.666667,"avgChangeRate":0.03832},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.010418},{"month":11,"riseRate":0.571429,"avgChangeRate":0.078824},{"month":12,"riseRate":0.428571,"avgChangeRate":0.054557}],"exchange":"SEHK","name":"信达生物","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信达生物,01801,信达生物股票,信达生物股票老虎,信达生物股票老虎国际,信达生物行情,信达生物股票行情,信达生物股价,信达生物股市,信达生物股票价格,信达生物股票交易,信达生物股票购买,信达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}